Enabling timely global access to a therapy for patients across the world can be challenging for pharmaceutical and biotech companies.

They may be unable to commercialise alone due to lack of footprint, resources and regional knowledge in a particular territory.

They may have to launch much later in some countries, and not at all in others.

They may experience unexpected disruption in the supply chain or decide to withdraw from a market or markets.

Ensuring access at these times may be outside the company’s core capabilities. It may be necessary to partner to enable quicker and broader access, via traditional licensing or more comprehensive commercialisation and distribution models . It may be necessary to make it available in unlicensed markets outside the usual commercial channels.

That’s when they need a trusted partner who can maximise reach and revenue through optimising access in both licensed and unlicensed markets, pre-launch or non-launch, who offers licensing or flexible distributor models.

Clinigen’s experienced teams in USA, Europe, Japan, Asia Pacific and Africa have unrivalled local expertise built up over 30 years. They provide an affiliate-like partnership model including Market Access, Regulatory, Medical, Sales and Marketing and Distribution services. They know the best way of commercialising new therapies and distributing existing ones, enabling both commercial and unlicensed access in their region.

Expertise that guides them in what’s feasible and what’s not. Insights that inform recommendations to add maximum value. And the reach, capacity and capability to deliver global access, supported by first-class logistics, customer service and regulatory know-how.

That makes Clinigen unique. Expert local knowledge backed up by regional scale and comprehensive support services. That’s why our clients only ever need one expert partner. Clinigen.